| Title |
New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, November 2015
|
| DOI | 10.2147/tcrm.s64915 |
| Pubmed ID | |
| Authors |
Felix-Martin Werner, Rafael Coveñas |
| Abstract |
Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipolar disorder. Like risperidone, cariprazine improves positive and negative schizophrenic symptoms, and ameliorates cognitive functions. Cariprazine induces extrapyramidal symptoms less often than risperidone and can cause acute akathisia. It is a prolactin-sparing antipsychotic drug and has a favorable metabolic profile. In acute mania in bipolar disorder, it treats manic symptoms significantly better than placebo. As a consequence of its improved adverse effects, cariprazine improves patients' quality of life to a greater extent than other second-generation antipsychotic drugs. Cariprazine is a promising antipsychotic drug in the treatment of schizophrenia, acute mania in bipolar disorder, and in schizophrenia with mania. In these patients, its long-term therapeutic effect and its action in comparison with other second-generation antipsychotic drugs, above all aripiprazole, remain to be tested in clinical trials. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 14% |
| Unknown | 6 | 86% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 43% |
| Practitioners (doctors, other healthcare professionals) | 3 | 43% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 25% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Master | 5 | 10% |
| Student > Doctoral Student | 4 | 8% |
| Other | 4 | 8% |
| Other | 9 | 19% |
| Unknown | 9 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 31% |
| Psychology | 9 | 19% |
| Agricultural and Biological Sciences | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Neuroscience | 2 | 4% |
| Other | 7 | 15% |
| Unknown | 10 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2018.
All research outputs
#5,505,970
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#272
of 1,308 outputs
Outputs of similar age
#68,501
of 295,288 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#11
of 53 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,288 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.